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DOI 10.1016/j.ccr.2011.10.014SUMMARYDespite its prevalence, the molecular basis of squamous cell carcinoma (SCC) remains poorly understood.
Here, we identify the developmental transcription factor Grhl3 as a potent tumor suppressor of SCC in
mice, and demonstrate that targeting of Grhl3 by a miR-21-dependent proto-oncogenic network underpins
SCC in humans. Deletion of Grhl3 in adult epidermis evokes loss of expression of PTEN, a direct GRHL3
target, resulting in aggressive SCC induced by activation of PI3K/AKT/mTOR signaling. Restoration of
Pten expression completely abrogates SCC formation. Reduced levels of GRHL3 and PTEN are evident in
human skin, and head and neck SCC, associated with increased expression of miR-21, which targets both
tumor suppressors. Our data define the GRHL3-PTEN axis as a critical tumor suppressor pathway in SCC.INTRODUCTION
The mammalian epidermis serves as an impermeable barrier,
protecting the organism from the hostile external environment.
It is maintained by a self-renewal process in which keratinocytes
proliferating in the basal layer detach from the underlying base-
ment membrane, withdraw from the cell cycle, and differentiate
while migrating toward the skin surface (Clayton et al., 2007;
Fuchs and Raghavan, 2002; Watt, 2001). Perturbation of the
balance between keratinocyte proliferation and differentiationSignificance
The molecular basis of SCC is poorly understood. Here, we
a potent tumor suppressor in SCC in both humans and mice.
tumor suppressor activity, providing the elusive explanation
the absence of genetic or epigenetic alterations to the gene.
that synchronously targets GRHL3 and PTEN leading to ampl
of both skin, and head and neck origins. We demonstrate that
to the PI3K/AKT-signaling pathway, with profound downregul
Canunderpins a wide range of skin pathologies. When disrupted
during embryogenesis, it results in a markedly thickened
epidermis with altered expression of structural proteins leading
to a failure of skin barrier formation (Koster, 2009). In adults it
is the central tenet of various disease states, including the
epidermal cancers, the most common of all human tumors
(Alam and Ratner, 2001; Rogers et al., 2010).
Although abnormal activation of the sonic hedgehog/patched
pathway is critical for the proliferation/differentiation imbalance
in basal cell carcinoma (Wetmore, 2003), the molecular basisidentify the developmental transcription factor GRHL3 as
We define Pten as the critical downstream effector of Grhl3
for the low levels of Pten expression in SCC that occur in
In humans we identify a miR-21 proto-oncogenic network
ification of PI3K/AKT/mTOR signaling and induction of SCC
Grhl3/PTEN-deficient SCC displays an oncogene addiction
ation of the MAPK/ERK pathway.
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(Ridky and Khavari, 2004). Studies in human tissue models
have provided evidence that activation of Ras signaling, in
concert with inhibition of NF-kB function, is sufficient for malig-
nant transformation of keratinocytes. In human tumors, Ras acti-
vation is most frequently due to mutations in codon 12, 13, or 61
of one of the threeRas genes (Bos, 1989). However, mutations in
Ras isoforms are found in only 22% of SCCs (Khavari and Rinn,
2007), although some tumors can display increased levels of
active Ras-GTP in the absence of a mutation (Dajee et al.,
2003). In the classical skin chemical carcinogenesis model in
mice, mutations in codon 61 of the H-Ras gene induced by the
topical application of 7, 12-dimethylbenz[a]anthracene (DMBA)
predominate (Abel et al., 2009). Activated Ras stimulates
multiple effectors including the Raf/MEK/ERK pathway, the
phosphatidylinositol 3-kinase (PI3K)/AKT/mTOR pathway, and
the guanine nucleotide exchange factors (Repasky et al.,
2004). Each of these has been clearly implicated in the patho-
genesis of keratinocyte hyperproliferation and dedifferentiation,
and/or overt SCC in mice (Gonza´lez-Garcı´a et al., 2005; Scholl
et al., 2007; Segrelles et al., 2007), although data from primary
human samples are less compelling, or completely lacking.
An alternate mechanism for activation of PI3K/AKT/mTOR
signaling in SCC is through loss of expression of the phospha-
tase and tensin homolog (PTEN) tumor suppressor gene.
Previous studies have suggested that activation of H-ras and
complete loss of Pten are mutually exclusive in skin carcinomas
(Mao et al., 2004). PTEN acts as the most important negative
regulator of the PI3K pathway, converting phosphatidylinositol
3,4,5-triphosphate (PIP3), the product of activated PI3K, to
phosphatidylinositol 4,5-biphosphate (PIP2) (Stambolic et al.,
1998; Maehama and Dixon, 1998). Inactivation of PTEN leads
to accumulation of PIP3, and as a consequence, increased
activity of the serine/threonine kinases PDK1 and AKT, which
promote cellular survival, cell cycle progression and growth,
angiogenesis, and cellular metabolism through phosphorylation
of numerous diverse cellular substrates (Manning and Cantley,
2007). AKT activation also leads to activation of themTOR kinase
complex 1 (mTORC1), resulting in activation of S6K1 and phos-
phorylation of 4EBP1, and enhanced protein translation through
multiple effector pathways. PTEN has been implicated in SCC in
both humans and mice (Ming and He, 2009; Suzuki et al., 2003).
Despite this, somatic mutations, gene deletions, and promoter
hypermethylation of PTEN have not been detected in human
SCC, suggesting that other mechanisms of inactivating the
genemay be involved in SCC pathogenesis (Ming and He, 2009).
Another tumor suppressor of SCC in humans and mice is IkB
kinase a (IKKa) (Liu et al., 2006, 2008; Maeda et al., 2007). Adult
mice with a targeted deletion of this gene in keratinocytes
develop epidermal hyperproliferation, perturbed expression of
differentiation markers, and ultimately, spontaneous SCC (Liu
et al., 2008). Constitutive deletion of IKKa during embryogenesis
leads to a thickened and undifferentiated epidermis, with
neonates dying of dehydration due to a profound skin barrier
defect (Hu et al., 1999; Takeda et al., 1999). These findings are
of considerable interest because they demonstrate that a key
regulator of keratinocyte proliferation/differentiation balance
during embryonic development can also play a major role as
a tumor suppressor in adulthood (Descargues et al., 2008).636 Cancer Cell 20, 635–648, November 15, 2011 ª2011 Elsevier IncWe have previously shown that mice lacking the Grainy head-
like 3 (Grhl3) gene exhibit a markedly thickened epidermis, per-
turbed expression of multiple epidermal differentiation markers,
and defective skin barrier formation, with newborn pups dying of
dehydration (Ting et al., 2005; Yu et al., 2006).Grhl3 is a member
of a highly conserved family of transcription factors critical for
epidermal development and homeostasis across a wide range
of species (Jane et al., 2005; Venkatesan et al., 2003;Wilanowski
et al., 2002). Expression of this gene is largely confined to the
surface ectoderm during embryogenesis, and in adulthood
occurs in tissues that arise from this embryonic layer, including
the skin, and lining of the oral cavity. The antecedent member
of this family in Drosophila, grainy head (grh) plays central roles
in cuticle formation and repair (Bray and Kafatos, 1991; Mace
et al., 2005). In view of the essential role played byGrhl3 in main-
taining the proliferation/differentiation balance in epidermal
ontogeny, and the burgeoning links between conserved devel-
opmental genes and cancer (Dean, 1998), we have further inves-
tigated the role of Grhl3 in adult skin homeostasis and skin
cancer development.
RESULTS
Grhl3 Deletion during Embryogenesis Causes
Epidermal Keratinocyte Hyperproliferation
Our initial experiments focused on the proliferative potential of
keratinocytes in the Grhl3 null mice. The epidermis in embryonic
day (E) 18.5 Grhl3/ animals was markedly thickened (Fig-
ure 1A), and expression of the proliferative marker PCNA was
expanded compared to wild-type epidermis, with mitotic cells
extending into the suprabasal layers (Figure 1B). This hyperpro-
liferation was cell intrinsic because keratinocytes cultured from
E18.5 Grhl3/embryos grew more rapidly than the wild-type
controls (Figure 1C), and displayed loss of cell-cell contact inhi-
bition, forming heaped up pseudo-tumors in the culture dish
(Figure 1D). They also displayed increased colony numbers in
soft agar (Figure 1E), strengthening the possibility that Grhl3
could play a tumor suppressor role in skin cancer in adult
mice. To investigate this, we generated mice carrying a condi-
tionally targetable Grhl3 allele, with loxP sites flanking exons 2
and 4 of the gene (see Figures S1A–S1C available online and
Experimental Procedures). Mice homozygous for the floxed
alleles (Grhl3fl/fl) were healthy and fertile, and when crossed
with Grhl3+/ mice carrying a B6-Cre transgene expressed at
the two-cell stage of development, generated Grhl3D//B6-
Cre+mice (whereD is the deleted floxed allele) that phenocopied
the Grhl3 null animals (Ting et al., 2003, 2005) (data not shown).
To delete Grhl3 in the skin, we crossed Grhl3fl/ mice with a line
carrying a keratin (K) 14-driven Cre transgene. Although patchy
deletion in the epidermis has been reported with this line as early
as E13.5 (using a ROSA cross) (Jonkers et al., 2001), analysis of
the epidermis in E18.5 Grhl3fl//K14Cre+ embryos revealed less
than 20% deletion (Figure S1D), and all E18.5 Grhl3fl//K14Cre+
embryos displayed normal skin barrier formation (data not
shown). High levels of deletion (>95%) of the Grhl3fl allele
were only detected after birth (from P1 onward) (Figure S1D),
and consistent with this, expression of Grhl3 in the deleted
skin was markedly reduced (Figure S1E). Interestingly, the
Grhl3D//K14Cre+ mice displayed no defect in skin barrier.
Figure 1. Hyperproliferation of Grhl3 Null Keratinocytes
(A and B) Histology and PCNA IHC on skin from E18.5 wild-type (WT) and
Grhl3/ (KO) embryos. E, epidermis; D, dermis; hf, hair follicle. Scale bars
correspond to 50 mm.
(C–E) Cell numbers, appearance, and soft agar colony numbers of cultured
keratinocytes from WT and KO E18.5 embryos. For keratinocyte cultures,
2.6 3 104 cells were seeded at day 0. For soft agar, 3.4 3 105 cells were
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Canfunction at P7 (data not shown), and appeared normal at 8weeks,
indicating that although Grhl3 was essential for establishment
of the barrier in utero, it was not essential for its maintenance
after birth.
Mice with Grhl3 Deletion in Keratinocytes Display
Enhanced Susceptibility to Chemical-Induced
and Spontaneous SCC
To examine the role of Grhl3 in skin tumorigenesis, we used
a well-established chemical carcinogenesis protocol on cohorts
ofGrhl3D//K14Cre+ mice and wild-type controls (n = 18 in each
group), in which tumors were initiated by topical application of
DMBA, and promoted by twice-weekly 12-O-tetradecanoyl-
phorbol-13-acetate (TPA) (Abel et al., 2009). Papilloma formation
was observed within 4 weeks in the Grhl3D//K14Cre+ animals,
but not until 13 weeks in any controls, by which time 100% of
the mutant mice had developed tumors (Figure 2A). The rapidity
of tumor formation was striking; particularly because the back-
ground strain of the mutant animals (C57Bl/6) is notoriously
resistant to chemical-induced tumor formation (Sundberg
et al., 1997). Total tumor numbers were also markedly higher in
the mutant versus wild-type mice (Figure 2B), and many of the
papillomas progressed on to form SCCs (Figure 2C), a rare event
in the wild-type mice. The SCCs grew rapidly and were often
multiple (Figures 2D), and histologically were poorly differenti-
ated with numerous mitoses (Figure 2E). The epidermis adjacent
to the tumors was markedly thickened compared to wild-type
mice and resembled the epidermis fromGrhl3 null embryos (Fig-
ure S2, H&E). Consistent with this, perturbed expression of the
terminal differentiation markers filaggrin and involucrin, and the
Ks 5, 6, and 10 in the Grhl3-deleted adult skin also mirrored
the changes observed in the Grhl3 null embryos (Figure S2A)
(Yu et al., 2006). Expression of Grhl3 was markedly reduced in
treated skin prior to the onset of tumors, and completely absent
in both papillomas and SCCs from the Grhl3D//K14Cre+ mice
(Figure 2F). Tumors were also observed with high frequency in
Grhl3D//K14Cre+ animals, but not wild-type controls (n = 10 in
each group) treated with TPA alone (Figure 2G; Figure S2B),
suggesting that loss of Grhl3 is sufficient for disease initiation.
With aging, 100% of the untreated Grhl3D//K14Cre+ mice
developed epidermal hyperplasia and spontaneous tumors
that were predominantly squamous papillomas or carcinomas
affecting the snout and neck (Figure 2H). Identical findings
were obtained when mouse mammary tumor virus (MMTV)-Cre
transgenic mice were used to delete Grhl3 in keratinocytes
(data not shown) (Liu et al., 2008). These snout and neck tumors
in both Grhl3D/ lines phenocopied changes observed in mice
with a keratinocyte-specific deficiency of the tumor suppressor,
Pten (Suzuki et al., 2003).
PTEN Is a Direct Transcriptional Target Gene of GRHL3
The DNA consensus-binding site for human GRHL3 and its
Drosophila homolog, grh, has been conserved across 700million
years of evolution (Ting et al., 2005). On this basis we predictedseeded at day 0. Arrow shows pseudo-tumor. The differences in cell number
were statistically significant (p < 0.03) using a Student’s t test. Error bars
represent the standard deviation (±SD). The scale bars in (D) correspond
to 50 mm.
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Figure 2. Grhl3 Functions as a Tumor Suppressor in Mice
(A–C) Tumor incidence, number, and malignant potential in DMBA/TPA-treated WT and Grhl3D//K14Cre+ mice. The differences in tumor incidence (p < 0.001),
number (p < 0.05), and malignant potential (p < 0.001) were statistically significant using a Student’s t test.
(D) Macroscopic appearance of DMBA/TPA-treated WT and Grhl3D//K14Cre+ mice at 15 weeks.
(E) Histology of SCC at low (left panel) and high magnification from DMBA/TPA-treated Grhl3D//K14Cre+ mice. (See also Figure S2A.)
(F) Grhl3 expression levels by Q-RT-PCR in normal skin (NAD), papillomas (pap), and SCCs from DMBA/TPA-treated WT and Grhl3D//K14Cre+ mice. The
differences in expression between wild-type and Grhl3D//K14Cre+-derived tissues were significant (p < 0.001) using a Student’s t test. Mean of three inde-
pendent experiments ±SD.
(G) Tumor incidence in WT and Grhl3D//K14Cre+ mice treated with TPA alone.
(H) Macroscopic and microscopic appearance of spontaneous snout tumor in Grhl3D//K14Cre+ mice. (See also Figure S2B.)
Scale bars correspond to 200 mm (white) and 50 mm (black).
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across a wide range of species. Therefore, we interrogated
a customized data set of genomic regions located within 10 kb
of gene transcriptional start sites that are conserved in placental
mammals with the GRHL3 consensus (and highly related
sequences), an approach we had successfully employed to
identify a key GRHL3 target in wound repair (Caddy et al.,
2010). We identified a highly conserved site in the promoter
region of thePten gene (Figure 3A) (Li et al., 1997), and confirmed
specific binding of GRHL3 to this site in vitro in electrophoretic
mobility shift assays (EMSA) (Figure 3B), and in vivo by chromatin
immunoprecipitation (ChIP) (Figure 3C). We also demonstrated
that transcriptional activation of the Pten promoter by Grhl3
was dependent on the integrity of this site in reporter gene638 Cancer Cell 20, 635–648, November 15, 2011 ª2011 Elsevier Incassays (Figure S3A). Consistent with Pten being a direct target
of GRHL3, expression of the gene was markedly reduced in
the skin of Grhl3 null E18.5 embryos at both RNA and protein
level (Figure 3D).
Loss of PTEN leads to accumulation of PIP3, and as a conse-
quence, increased activity of the serine/threonine kinases PDK1
and AKT, with resultant activation of mTORC1 (Manning and
Cantley, 2007). This leads to activation of S6K1 and phosphory-
lation of 4EBP1 and ribosomal protein S6, which provide a robust
readout of mTORC1 signaling (Guertin and Sabatini, 2007; Ma
and Blenis, 2009). Analysis of these downstream effectors of
PI3K signaling in epidermis from Grhl3 null embryos revealed
increased levels of AKT, PDK1, S6, and 4EBP1, as well as their
phosphorylated forms, p-AKT, p-PDK1, p-S6, and p-4EBP1.
Figure 3. PTEN Is a Direct Transcriptional Target Gene of GRHL3
(A) Alignment of the promoter regions of PTEN genes from the indicated species. The GRHL3 DNA consensus sequence is enlarged and bolded. (See also
Figure S3A.)
(B) EMSA of recombinant (r) GRHL3 binding to the Pten promoter probe. A 100-fold molar excess of unlabelled cold competitor probes (Pten orGrhl3 consensus)
was added in the indicated lanes. The migration of the specific GRHL3/DNA complex is arrowed.
(C) ChIP analysis of endogenous GRHL3 on the PTEN promoter. Chromatin from the human keratinocyte line (HaCaT) was immunoprecipitated using antisera to
GRHL3, and amplified with PTEN primers. Preimmune sera (IgG) and the muscle-specific MyoD promoter were used as negative controls, and the input
chromatin is shown.
(D) Q-RT-PCR (upper panel) and immunoblot (lower panel) of Pten expression in wild-type (WT) and Grhl3/ (KO) E18.5 skin. For Q-RT-PCR, bars represent
standard errors, andHPRT served as a reference. The difference in expression was statistically significant (*p < 0.02) using a Student’s t test. For the immunoblot,
actin served as the loading control. Error bars represent the standard deviation (±SD).
(E) Immunoblots of epidermal lysates from WT and KO E18.5 embryos probed with the stated antibodies. Actin and HSP70 served as loading controls. The fold
induction of the phosphorylated proteins normalized to the levels of their nonphosphorylated counterparts is shown below each blot.
(F) IHC analysis of skin from WT and KO E18.5 embryos using the stated antibodies. Arrow in the lower right panel indicates p-AKT staining in the basal and
adjacent suprabasal layers. Scale bars correspond to 200 mm (white) and 50 mm (black). (See also Figure S3B.)
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Figure 4. Pten Is the Critical GRHL3 Target
Gene in Dysregulated Cell Growth and
PI3K/AKT Activation
(A) Increased susceptibility of Pten+//Grhl3+/
mice to DMBA/TPA-induced SCC. The difference
in SCC incidence between Pten+//Grhl3+/ and
Pten+//Grhl3+/+ mice (*) was significant (p < 0.05)
using the Student’s t test.
(B) Macroscopic appearance of DMBA/TPA-
treated Pten+/+/Grhl3+/, Pten+//Grhl3+/+, and
Pten+//Grhl3+/ mice at 20 weeks. P, papilloma;
K, kerato-acanthoma; S, SCC.
(C) Pten expression levels by Q-RT-PCR in normal
skin from Pten+/+/Grhl3+/, Pten+//Grhl3+/+, and
Pten+//Grhl3+/ mice. Error bars represent the
standard deviation (±SD). The differences in Pten
expression between the different lines (*) were
statistically significant (p < 0.05) using a Student’s
t test.
(D) Immunoblots using the stated antibodies of
lysates from GRHL3-kd and Scr HaCaT cells
grown in serum, or transduced with MSCV-based
retroviral supernatants carrying wild-type PTEN or
the C124S phosphatase dead PTEN mutant as
indicated. GAPDH served as the loading control.
Error bars represent the standard deviation (±SD).
(See also Figure S4A.)
(E) Growth kinetics of the cell lines listed in (D). A
total of 1 3 105 cells for each line was seeded at
day 0. The differences between the GRHL3-kd or
GRHL3-kd + C124S mutant and the GRHL3-kd +
wild-type PTEN or Scr cells at day 8 were signifi-
cant (p < 0.004) using the Student’s t test. Error
bars represent the standard deviation (±SD).
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proteins reflects a high level of mTORC1 signaling (Ma and
Blenis, 2009). The levels of the catalytic p110a isoform and the
p85 regulatory subunit of the PI3K protein, which lie upstream
of PTEN, were not altered. PTEN levels were markedly reduced
in the basal layer of the epidermis, and coincident with this, the
levels of p-AKT were increased in this layer, and the adjacent
suprabasal layer (Figure 3F). The size of the cells in the basal
layer was also increased (Figure S3B), a feature common to cells
from mice lacking Pten (Groszer et al., 2001).
To determine whether Grhl3 and Pten interacted epistatically,
we intercrossed mice carrying heterozygous deletions of the two640 Cancer Cell 20, 635–648, November 15, 2011 ª2011 Elsevier Inc.genes to generate compound heterozy-
gotes (Grhl3+//Pten+/), and compared
these animals with Grhl3+//Pten+/+ and
Grhl3+/+/Pten+/ controls in the chemi-
cal-induced tumor model (n = 10 in each
group) (Figure 4A). Although mice hetero-
zygous for Pten alone (Grhl3+/+/Pten+/)
display increased susceptibility to
DMBA/TPA-induced tumors (Mao et al.,
2004), the additional loss of a single
Grhl3 allele enhanced both the rapidity
of cancer development and the number
of mice with multiple aggressive SCCs
(Figure 4B). Conversely, the restorationof Pten to wild-type status in the Grhl3+//Pten+/+ mice almost
completely safeguarded these animals against SCC formation.
The susceptibility of the different genotypes to SCC was re-
flected in their levels of Pten expression (Figure 4C). Taken
together, these data suggest that Pten is the critical downstream
target of Grhl3 for prevention of SCC. To confirm this in a human
model, we generated a human keratinocyte cell line (HaCaT)
in which the expression of GRHL3 had been knocked down
using a specific shRNA containing lentivirus (GRHL3-kd) (Fig-
ure 4D) (Caddy et al., 2010). A line transduced with a scrambled
control (Scr) shRNA served as the control. In keeping with our
earlier findings, the level of PTEN was markedly reduced in the
Cancer Cell
A Proto-Oncogenic Network in SCCGRHL3-kd line compared to control, and p-AKT and p-S6 levels
were increased in these cells in both the presence (Figure 4D)
and absence of serum (Figure S4). This latter result was consis-
tent with the resistance to growth factor and nutrient withdrawal
observed with constitutive PI3K activation in tumor cell lines
(Kalaany and Sabatini, 2009). The GRHL3-kd cells also prolifer-
ated more rapidly than the Scr cells (Figure 4E). Reintroduction
of wild-type PTEN into the GRHL3-kd line restored the inhibition
of phosphorylation of AKT and S6 (Figure 4D), and led to
suppression of cell growth (Figure 4E). In contrast, introduction
of the C124S phosphatase dead PTEN mutant (Myers et al.,
1998), to equivalent levels to that achieved with the wild-type
protein, failed to inhibit AKT and S6 phosphorylation (Figure 4D),
and also failed to suppress the enhanced proliferation of the
GRHL3-kd cells (Figure 4E). These findings suggest that Pten
is the critical downstream target of GRHL3 in tumorigenesis.
Activation of PI3K/AKT and Repression of Ras/MAPK/
ERK Signaling in Grhl3-Deficient Tumors
We next compared PTEN levels and PI3K signaling in unaffected
skin, papillomas, and SCCs derived from both wild-type and
Grhl3D//K14Cre+ mice (Figures 5A and 5B). Cellular prolifera-
tion in the SCCs was demonstrated by PCNA staining (Fig-
ure S5A). Loss of GRHL3 was associated with a reduction in
PTEN in unaffected skin, and almost complete loss in papillomas
and SCCs that was not observed in the wild-type skin or tumors.
This was accompanied by increased levels of p-S6 and p-AKT in
the tumors from Grhl3D//K14Cre+ mice. Although p-S6 levels
were also increased in the tumors from wild-type mice, p-AKT
expression was weak, suggesting that the increase in p-S6
was due to other pathways feeding into the mTORC1 pathway
below the level of AKT (Carracedo and Pandolfi, 2008). Of note
the increase in p-AKT in the SCC from Grhl3D//K14Cre+ mice
compared to wild-type controls was due to both the number of
positively staining cells in the tumors and the staining intensity
(Figures S5B and S5C).
Previous studies have suggested that activation of H-ras and
complete loss of Pten are mutually exclusive in skin carcinomas
(Mao et al., 2004). Our findings confirmed this because we
detected no mutations in codons 12, 13, or 61 in the H-Ras
gene in tumors derived from Grhl3D//K14Cre+ mice, whereas
16% of tumors from the wild-type mice carried mutations in
these codons (Figure 5C). Similar frequencies of H-Ras muta-
tions have been detected in series of human SCC (Boukamp,
2005). We also observed an almost complete absence of
p-ERK1/2 in tumors from the Grhl3D//K14Cre+ mice despite
levels of ERK1/2 that were comparable to unaffected skin, and
skin from wild-type controls (Figures 5D and 5E). This finding
was comparable to the reduction in p-ERK1/2 that we had previ-
ously described in the epidermis of Grhl3 null embryos (Hislop
et al., 2008). In contrast the levels of p-ERK1/2 in tumors from
wild-type mice were markedly elevated (Figures 5D and 5E).
A miR-21-Dependent Proto-Oncogene
Network Targets GRHL3 and PTEN
To establish the relevance of our mouse findings in the human
system, we analyzed the expression of GRHL3 by Q-RT-PCR
in 37 consecutive primary human SCCs, and the adjacent nontu-
mor-affected epidermis isolated by laser capture microdissec-Cantion (LCM). In almost all cases GRHL3 levels were markedly
reduced in the tumors compared to the adjacent epidermis,
with expression reduced by more than 90% in over half the
samples (Figure 6A). A coordinate reduction in PTEN expression
was also observed in these tumors (Figure 6A ; Figure S6A).
Interestingly, a similar reduction in GRHL3 and PTEN levels
was also observed in SCCs of head and neck origin (HNSCCs)
(Figure S6B), suggesting a common molecular mechanism for
cancers of this histological subtype. Sequence analysis of the
GRHL3 coding exons and splice donor and acceptor sites failed
to detect anymutations in the tumors, and themethylation status
of the CpG islands in the GRHL3 promoter was unchanged in
tumors compared to normal skin (data not shown).
An alternate mechanism for the reduction in GRHL3 expres-
sion in the tumors could be through overexpression of a specific
microRNA (miRNA), which have been shown in some contexts to
function as oncogenes by targeting tumor suppressors (Ham-
mond, 2006; Esquela-Kerscher and Slack, 2006; Garzon et al.,
2010). To examine this, we interrogated a miRNA array with total
RNA derived from two human SCCs with undetectable levels of
GRHL3, and their matched normal skin controls (Figure 6B). We
focused on miRNAs that were predicted to target GRHL3 using
the mirWIP database (Hammell et al., 2008). Of this set,
miR-21 exhibited the greatest differential between normal and
tumor tissue, and its sequence aligned with nucleotides
414–436 in the GRHL3 30UTR (Figure 6C). Interestingly, miR-21
has previously been shown to function as an oncogene by tar-
geting PTEN (Meng et al., 2007). We examined an additional
ten SCCs, and their matched controls, and demonstrated
a greater than 6-fold difference in miR-21 expression between
the two groups (Figure 6D). We confirmed that enforced expres-
sion of miR-21 (Figure S6C) could inhibit GRHL3 mRNA
expression in the human HaCaT cell line (Figure 6E), in keeping
with recent reports indicating that mRNA destabilization usually
comprised the major component of miR-dependent gene
repression (Baek et al., 2008; Selbach et al., 2008). Expression
of PTEN mRNA was also reduced in this line, consistent with
the effect on GRHL3, and with direct targeting of PTEN by
miR-21 (Figure 6F). GRHL3 and PTEN protein levels were also
markedly reduced in the miR-21 expressing HaCaT cells (Fig-
ure 6G), and this was accompanied by enhanced cell growth
(Figure S6D). We established that GRHL3 was a direct target
of miR-21, using a luciferase reporter linked to the GRHL3
30UTR (Figure 6H). Cotransfection of this construct with a
miR-21 expression vector into HEK293 cells resulted in amarked
reduction in luciferase activity compared to a Scr sequence, and
this was reversed when an antagomir of miR-21 (miRZip21)
was also transfected. Deletion of the miR-21 binding site in the
GRHL3 30UTR completely abrogated its effect (Figure 6H),
indicating that GRHL3 is a direct target of miR-21.
The miR-21-Dependent Proto-Oncogene Network
Is Active in Both Skin and HNSCC
To determine whether the miR-21-dependent proto-oncogene
network had broader relevance in SCC, we examined expres-
sion of miR-21, GRHL3, and PTEN in a range of human SCC cell
lines derived from both epidermal (SCC-13), and head and
neck (SCC-4, -9, -15, -25, and CAL-27) origins. All SCC lines
tested, except SCC-4, exhibited elevated levels of miR-21cer Cell 20, 635–648, November 15, 2011 ª2011 Elsevier Inc. 641
Figure 5. Skin and Tumors from Grhl3D/–/K14Cre+ Mice Exhibit PI3K Pathway Activation
(A) Immunoblot of lysates from epidermis (NAD), papillomas (Pap.), and SCCs fromwild-type andGrhl3D//K14Cre+mice probedwith PTEN and p-S6 antibodies.
Actin served as the loading control.
(B) IHC analysis of SCC from wild-type and Grhl3D//K14Cre+ mice using AKT and p-AKT antibodies. (See also Figures S5A–S5C.)
(C) Analysis of H-Ras mutations in tumors from wild-type and Grhl3D//K14Cre+ mice.
(D) Immunoblot of lysates from epidermis, papillomas, and SCCs from wild-type and Grhl3D//K14Cre+ mice probed with ERK1/2 and p-ERK1/2 antibodies.
The actin loading control is shown and is the same as for (A).
(E) IHC analysis of SCC from wild-type and Grhl3D//K14Cre+ mice using ERK1/2 and p-ERK1/2 antibodies.
Scale bars correspond to 200 mm (white) and 50 mm (black).
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A Proto-Oncogenic Network in SCCcompared to HaCaT cells, with corresponding reductions in
both GRHL3 and PTEN levels (Figure 7A). To assess the con-
sequences of inhibition of miR-21 in HNSCC, we utilized the
miRZip21 antagomir in the SCC-9 cell line, achieving a substan-
tial reduction in miR-21 levels compared to cells transduced
with a Scr control (Figure 7B). This resulted in a greater than
10-fold induction of GRHL3 expression at both RNA (Figure 7C)642 Cancer Cell 20, 635–648, November 15, 2011 ª2011 Elsevier Incand protein (Figure 7D) level, resulting in increased levels of
PTEN, inhibition of PI3/AKT signaling (Figure 7D), and marked
inhibition of cell proliferation (Figure 7E). These finding suggest
that activation of the miR-21-dependent proto-oncogene
network may be a common molecular mechanism in SCC of
different tissue origins, and that targeting of this network may
have therapeutic potential..
Figure 6. miR-21-Induced Loss of GRHL3 and PTEN Expression in Human SCC
(A) Quantification of GRHL3 and PTEN expression levels by Q-RT-PCR in human SCCs isolated by LCM, normalized to expression in the adjacent nontumor-
containing tissue. The differences in GRHL3 (***) and PTEN (**) expression between normal tissues and SCCs were statistically significant (p < 0.02 and p < 0.05,
respectively) using a Student’s t test. Error bars represent ±SEM. (See also Figures S6A and S6B.)
(B) Heat map of the relative expression of miRNAs predicted to targetGRHL3 in two human SCCs and the adjacent normal epidermis. The fold change in tumor (T)
versus normal (N) is shown.
(C) Alignment between miR-21 and the 30UTR of human GRHL3.
(D) Quantification of humanmiR-21 expression levels relative to U6 byQ-RT-PCR in ten SCCs and their matched controls. The difference inmiR-21 expression (**)
between normal tissues and SCCs was statistically significant (p < 0.02) using a Student’s t test. Error bars represent the standard deviation (±SD).
(E) GRHL3 and (F) PTEN expression quantitated by Q-RT-PCR and normalized to b-actin in HaCaT cells overexpressing miR-21 or a Scr control. Error bars
represent the standard deviation (±SD).
(G) Immunoblots of lysates from control and miR-21 overexpressing HaCaT cells probed with the stated antibodies. Actin and HSP70 served as the loading
controls. (See also Figures S6C and S6D.)
(H) Luciferase activity of the wild-type (30UTR) or mutant (Mut21)GRHL3 30UTR reporter constructs transfected into HEK293 cells in the presence and absence of
expression vectors carrying miR-21 or its antagomir (miRZip21) as indicated. Expression of b-galactosidase from a cotransfected reporter construct was used as
control for transfection efficiency. The differences in relative luciferase activity between the GRHL3 30UTR construct transfected alone, or cotransfected with
miR-21 alone (**), or miR-21 and miRZip21 (*) were statistically significant (p < 0.01 and p < 0.05, respectively) using a Student’s t test. Error bars represent the
standard deviation (±SD).
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Figure 7. The miR-21-Dependent Proto-Oncogene Network Is Active in Both Skin and HNSCC Cell Lines
(A) miR-21, GRHL3, and PTEN expression levels in SCC cell lines relative to HaCaT cells.
(B) Quantification of miR-21 expression by Q-PCR in SCC-9 cells transinfected with the lentiviral vector-basedmiR-21 antagomir (miRZip21) or a Scr control. The
difference in expression (**) was statistically significant (p < 0.005) using a Student’s t test.
(C) Quantification of GRHL3 expression by Q-PCR in SCC-9 cells transinfected with the lentiviral vector-based miR-21 antagomir (miRZip21) or a Scr control.
The difference in expression (***) was statistically significant (p < 0.002) using a Student’s t test.
(D) Immunoblots using the stated antibodies of lysates from SCC-9 cells transduced with a lentivirus carrying the miRZip-21 or Scr control. Actin served as the
loading control.
(E) Growth kinetics of the cell lines listed in (D). A total of 4 3 104 cells for each line was seeded at day 0. The differences between the SCC-9 + miRZip-21 and
SCC-9 + Scr cells at day 8 were significant (**) (p < 0.003) using the Student’s t test.
Error bars represent the standard deviation (±SD) in (A)–(C) and (E).
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Our data define theGrhl3 gene as a potent suppressor of SCC of
the skin in mammals, acting through the direct transcriptional
regulation of Pten. Supporting this conclusion are phylogenetic,
biochemical, and expression data coupledwith functional rescue
studies in vitro in a human system, and in vivo in the mouse. In
addition, clear parallels exist between Grhl3-deficient mice and
mice lacking Pten in the adult epidermis, although the phenotype
in the latter animals is somewhat variable, and is dependent on
the strategy utilized for gene deletion (Suzuki et al., 2003; Yao
et al., 2006; Mao et al., 2004). Our findings also implicate Grhl3
in the pathogenesis of HNSCC in humans, providing possible
alternate therapeutic strategies for targeting cancers that are
often associated with an extremely poor prognosis.
Although PTEN has been thought to be constitutively ex-
pressed, and minimally regulated in normal tissues (Salmena
et al., 2008), our findings refute this paradigm in one setting by
establishing the pivotal importance of tissue-specific control of
Pten expression in suppression of SCC. The integral function
of Grhl3 in this process, coupled with its role in maintaining the
balance between keratinocyte differentiation and proliferation,
defines Grhl3 as a critical innate surveillant to prevent skin
cancer. In this regard its function is similar to IKKa, which also
induces keratinocyte terminal differentiation and prevents SCC
(Liu et al., 2008; Park et al., 2007). However, in contrast
to IKKa-deficient tumors that exhibit EGFR-induced ERK
activation, loss of Grhl3 results in exclusive upregulation of
PI3K/AKT/mTOR signaling, with a complete loss of p-ERK
expression and no change in the levels of p-EGFR (Figure S3C).
The absence of Ras mutations and the marked downregulation
of the MAPK/ERK-signaling pathway in the tumors from
Grhl3D//K14Cre+ mice are similar to the findings observed in
Pten-deficient mice (Mao et al., 2004), indicating that in the
absence of Pten, this pathway is dispensable for SCC formation.
Similar results were also observed in RU486-inducible K14.Cre/
Ptenfl/flmice that coexpress anHa-Ras transgene, in which TPA-
mediated tumor progression involved PTEN-associated path-
ways rather than Ras activation (Yao et al., 2006).
Although we have now identified several GRHL3 target genes
that are involved in the diverse developmental processes
regulated by this transcription factor (Caddy et al., 2010; Ting
et al., 2005), the loss of Pten alone appears to be sufficient for
the increased susceptibility of the Grhl3-deficient mice to both
chemical-induced and spontaneous SCC. This is illustrated by
the profound difference in cancer susceptibility between
Grhl3+//Pten+/+ mice (that develop no tumors) and Grhl3+//
Pten+/ animals (that display multiple aggressive SCC)—with
these two lines differing only by the addition of a single functional
Pten allele. A substantial difference in SCC susceptibility was
alsoobservedbetweenGrhl3+/+/Pten+/miceand thecompound
heterozygotes, consistent with recent data showing that subtle
differences in Pten expression levels can have profound conse-
quences on cancer susceptibility (Alimonti et al., 2010). Our
data in GRHL3-kd keratinocytes also indicate that PTEN is the
critical downstream target of GRHL3 in the human system, with
wild-type, but not a phosphatase-dead mutant PTEN, able to
repress PI3K/AKT/mTOR signaling and inhibit cell hyperprolif-
eration. This is further supported by our studies on the SCC9Cancell line, in which miRZip21-induced enhanced expression of
GRHL3 leads to upregulation of PTEN levels, suppression of
PI3K/AKT signaling, and reduced cell proliferation.
The reduced expression of both GRHL3 and PTEN mediated
by upregulation of miR-21 in human skin SCC explains the
long-standing paradox of loss of PTEN expression in the
absence of genetic or epigenetic alterations to the gene (Ming
and He, 2009). The coordinate targeting of both tumor suppres-
sors by miR-21 provides a classic example of the emerging
theme of miRNA-dependent amplification of signaling cascades,
which are evident in both normal and cancerous tissues (Inui
et al., 2010). In this setting the synchronous regulation of the
pathway inhibitor (PTEN) and its transcriptional regulator
(GRHL3) by a solitary miR (miR-21) establishes a proto-onco-
genic network involving enhanced PI3K/AKT/mTOR signaling
in these tumors. The extension of our findings from skin SCC
to HNSCC is in keeping with the common embryonic origins of
these tissues, and the expression of Grhl3 in all adult epithelium
derived from the developing surface ectoderm. It is also consis-
tent with previous studies identifyingGRHL3 as a gene exhibiting
reduced expression in primary and metastatic HNSCC (Nguyen
et al., 2007; Rickman et al., 2008), andwith the increased expres-
sion of miR-21 reported in multiple HNSCC series (Volinia et al.,
2006; Avissar et al., 2009; Hui et al., 2010).
Emerging from our work is an increased rationale for the use of
direct inhibitors of PI3K/AKT/mTORC1 signaling and/or antago-
nists of miR-21 in the treatment of SCC. Recent studies have
identified an mTORC1-PI3K-dependent negative feedback
loop regulating MAPK/ERK signaling in cancer, with increased
p-ERK levels observed in tumors treated with the TORC1 inhib-
itor RAD001 (Carracedo et al., 2008). It will be of considerable
interest to determine whether Grhl3-dependent skin SCCs
display activation of MAPK/ERK signaling when treated with
TORC1 inhibitors, or alternatively, exhibit true oncogene addic-
tion to constitutively active PI3K/AKT/mTOR signaling. The latter
finding may pave the way for novel therapeutic interventions in
invasive SCC of the skin. In the context of HNSCC, new treat-
ments have focused on inhibitors of EGFR, although targeting
of the PI3K/AKT pathway is also under investigation (Leemans
et al., 2011). As with other cancers, the PTEN expression status
may influence response to EGFR inhibitors (Jhawer et al., 2008),
and antagonists of miR-21may offer benefits as single agents, or
in combination with agents such as cetuximab.
EXPERIMENTAL PROCEDURES
Generation of Experimental Animals
All experiments were preapproved by The University of Melbourne Animal
Ethics Committee. The generation and genotyping of Grhl3+/ mice have
been described previously (Ting et al., 2003). The conditional Grhl3 targeting
vector was constructed and validated as detailed in the Supplemental Exper-
imental Procedures (Figures S1A–S1C). Grhl3+/ mice were crossed with
K14Cre+ transgenic mice (Jonkers et al., 2001), and the resultant animals
were crossed with Grhl3fl/fl mice to provide the Grhl3D//K14Cre+ experi-
mental animals (where D is the deleted floxed allele). Pten+/ mice were kindly
provided by Dr. Tak Mak, and intercrossed with Grhl3+/ mice to generate
compound heterozygotes.
Tumor Induction and Skin Barrier Analysis in Mice
Tumors were induced in mice through the application of 25 mg DMBA (Sigma-
Aldrich) in acetone to a shaved area on the back followed 1 week later bycer Cell 20, 635–648, November 15, 2011 ª2011 Elsevier Inc. 645
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30 weeks. In some experiments TPA was applied without DMBA initiation.
Skin barrier analysis was performed as previously described (Hardman
et al., 1998).
RNA Preparation and Q-RT-PCR
For gene expression analysis, normal skin from E18.5 wild-type and Grhl3/
embryos, and adult wild-type and Grhl3D//K14Cre+ mice, and papillomas
and SCC from wild-type and Grhl3D//K14Cre+ mice were homogenized in
TRIzol (Invitrogen) andRNA extracted according to themanufacturer’s instruc-
tions. Q-RT-PCR was carried out as described previously (Ting et al., 2003)
with primer sequences shown in the Supplemental Experimental Procedures.
A Student’s t test was used to determine statistical difference in expression
levels with p values <0.05 considered significant, and results were analyzed
using Prism (GraphPad). The error bars in all expression analyses represent
the standard error of the mean (SEM).
ChIP and EMSA
ChIP was performed as described previously (Wilanowski et al., 2008), with
anti-GRHL3 antibodies (Aviva Systems Biology, San Diego, CA). EMSAs
were performed using recombinant mouse GRHL3 protein, and oligonucleo-
tides containing the conserved GRHL3-binding site in the Pten promoter.
The DNA consensus-binding site for GRHL3 was used as a cold competitor
(Ting et al., 2005). Primer and oligonucleotide sequences for the Pten promoter
are shown in the Supplemental Experimental Procedures.
Immunoblot Analysis and IHC
Immunoblotting and IHC methodologies and the antibodies employed are
detailed in the Supplemental Experimental Procedures. For quantification of
IHC, eight images (203) were taken per tumor and the positive p-AKT cells
counted. The staining intensity of the tumor was quantified using MetaMorph
image analysis software and plotted as percentage of staining intensity of the
total area (Hambardzumyan et al., 2008).
shRNAs and Retroviral Infection
The shRNA target oligonucleotides for Grhl3 and the Scr were cloned into the
pSUPER.retro.neo+GFP vector using the BglII and HindIII sites. The target
sequences and generation of viruses are detailed as previously described
(Caddy et al., 2010). HaCaT cells were transduced over a 24 hr period, and
GFP-positive cells were selected by FACS, and cultured for 8 days, or har-
vested for preparation of lysates. Knockdown of GRHL3 expression was
confirmed by immunoblot using antibodies to GRHL3 and GAPDH. For
expression of wild-type PTEN, or the phosphatase dead C124S PTENmutant
in GRHL3-kd cells, the respective cDNAs were cloned into MSCV-DSRed
using the BamHI and XhoI sites. PTEN expression was confirmed in DSRed+
cells by immunoblot using PTEN antibody, and GAPDH as a loading control.
LCM
Deidentified surgical specimens of SCC resected from patients (including
tumor and adjacent normal tissue) were embedded in OCTmedium and stored
at 80C. The sections were stained with HistoGene LCM Frozen Staining Kit
just before commencing LCM. The cryosections (8 mm) were microdissected
using a Veritasmicrodissection instrument (Arcturus) according to the stan-
dard protocol. Tumor tissues and normal tissues were captured onto CapSure
Macro LCM Caps. RNA extraction and amplification were performed accord-
ing to the manufacturer’s instructions. The reagents for staining, RNA extrac-
tion, and RNA amplification were obtained from Arcturus. Q-RT-PCR was
performed as detailed above. Ethics approvals were obtained from the
Victorian Tissue Biobank and the Human Research Ethics Committee of the
Royal Melbourne Hospital.
Mutational Analysis of H-ras
PCR primers amplifying codons 12, 13, and 61 were designed on the basis of
genomic DNA sequences for H-ras. Mutations were detected by sequencing
as previously described (Ise et al., 2000). Themutationswere further confirmed
by restriction fragment length polymorphism (RFLP) analysis as previously
detailed (Jaworski et al., 2005).646 Cancer Cell 20, 635–648, November 15, 2011 ª2011 Elsevier IncLuciferase Assays
Reporter gene analysis of the Pten promoter is detailed in the Supplemental
Experimental Procedures. For analysis of miR-21 regulation of GRHL3, the
30UTR region of human GRHL3 containing the predicted site for miR-21 was
subcloned into the pMIR-REPORT luciferase vector (pMIR-GRHL30UTR lucif-
erase) (Applied Biosystems). A mutant construct (Mut21) was generated by
deleting 10 bp (419–428) from the miR-21 site in the 30UTR of GRHL3
(pMIR-GRHL30UTR-Mut21 luciferase). Both constructs (0.5 mg) were trans-
fected into HEK293T cells with the pMIR-b-galactosidase vector. After 15 hr,
the miR-21 precursor construct was coinfected with and without the lentivec-
tor-based antagomir to miR-21 ‘‘miRZip-21’’ (System Biosciences). Firefly
luciferase wasmeasured 48 hr after transfection/infection using the Dual-Light
Chemiluminescent Reporter Gene Assay System (Applied Biosystems), as per
the manufacturer’s instructions, and normalized to b-galactosidase activity to
control for differences in transfection efficiency.ACCESSION NUMBERS
The data set for the GeneChip miRNA Array has been deposited in the Gene
Expression Omnibus database with accession code GSE32868.SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures and Supplemental Experimental
Procedures and can be found with this article online at doi:10.1016/j.ccr.2011.
10.014.
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